NCT05535023 2023-09-13
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT04001413 2022-07-29
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT04044950 2020-09-22
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn